Year None2020201920182017 Dec 03, 2020 F-star Therapeutics Announces First Patient Dosed in First-in-Class FS120 Phase 1 Clinical Trial PDF Version Nov 24, 2020 F-star Therapeutics Announces Approval of Clinical Trial Application for FS222 PDF Version Nov 20, 2020 F-star Therapeutics Completes Combination with Spring Bank Pharmaceuticals PDF Version Nov 11, 2020 F-star Therapeutics to Present New Clinical and Mechanistic Data on its LAG-3/PD-L1 Tetravalent Bispecific Antibody, FS118, at the SITC 2020 Virtual Annual Meeting Oct 22, 2020 F-star Therapeutics to Present at SITC 2020 Virtual Annual Meeting Sep 09, 2020 F-star Therapeutics to Participate in H.C. Wainwright & Co. 22nd Annual Investment Conference Aug 05, 2020 F-star Therapeutics to Participate in BTIG Virtual Biotechnology Conference Jul 30, 2020 Spring Bank Pharmaceuticals and F-star Therapeutics Agree to Combine to Pursue Mission of Creating Next Generation Immunotherapies Jul 16, 2020 Merck KGaA, Darmstadt, Germany Takes an Early Option in Immuno-Oncology Collaboration Jun 22, 2020 F-star Therapeutics Presents Data on FS222 at 2020 AACR Annual Meeting Pagination Current page 1 Page 2 Next page Next
